


Coronaviruses and SARS-CoV-2

Dr Richard J. P. Brown


Department for Molecular and
Medical Virology

04.06.2025




Goals for today's lecture

- Understanding about the coronavirus replication cycle
- Overview about highly pathogenic coronaviruses
- Update: SARS-CoV-2 and COVID-19





Coronaviruses






Coronaviruses

- Family: *Coronaviridae*
- Genus: Coronavirus
- Enveloped
- Size: 80 – 150 nm
- Genome: 27 – 32 kb
- ss (+) RNA




Coronaviruses – Epidemiology


- Human Coronaviruses are endemic worldwide
- Cause approx. 15% of the yearly common colds
- Three pathogenic human Coronaviruses
 - SARS-CoV
 - MERS-CoV
 - SARS-CoV-2






Coronaviruses - Genera





- 4 Genera (Alpha-, Beta-, Gamma-, Deltacoronaviren)
- Coronaviruses can infect many species
- A zoonotic origin is suspected for all human CoVs




Coronaviruses - Zoonosis





Past – Present – Future?




Genomic Organization and Replication Cycle




Coronaviruses –Genomic organisation




Coronaviruses – Structural proteins





- Spike glycoprotein (S)
 - Binds receptor
 - Induces fusion
 - Target of neutralizing antibodies
- Nucleocapsid phosphoprotein (N)
 - Binds viral RNA
 - Target of cellular immunity
- Membrane glycoprotein (M)
 - Determines budding
 - Triggers virus assembly
- Envelope protein (E)
 - Involved in assembly and release



Coronaviruses – Replication cycle





Coronaviruses - Receptor




Coronavirus - entry


**Virus spike protein
Diagram**





**Virus spike protein
Crystallographic structure seen by electron microscopy
(PDB ID: 6VXX-PDB)**




Primary Structure




Coronavirus - entry



Coronaviruses – Replication cycle



Coronaviruses - Polyprotein



nsp1 Host mRNA degradation, translation inhibition

nsp2 Unknown

nsp3 Ubl Mac I-III DPUP Ubl PL^{pro} TM Y Polyprotein processing, de-ADP-ribosylation, deubiquitination, interferon antagonist, DMV formation

nsp4 TM DMV formation

nsp5 M^{pro} Polyprotein processing, inhibition of interferon signalling

nsp6 TM DMV formation

nsp7 Cofactor for RNA-dependent RNA polymerase

nsp8 Pr Primase or 3'-terminal adenylyltransferase, cofactor for RNA-dependent RNA polymerase

nsp9 Binding of single-stranded RNA

nsp10 Cofactor for nsp14 and 16

nsp11 Unknown


nsp12 NiRAN RdRP RNA-dependent RNA polymerase, nucleotidyltransferase

nsp13 ZBD HEL Helicase, RNA 5' triphosphatase


nsp14 ExoN NMT 3' to 5' exoribonuclease, proofreading, RNA cap formation, guanosine N7-methyltransferase

nsp15 EndoU Endoribonuclease, evasion of immune response

nsp16 OMT RNA cap formation, ribose 2'-O-methyltransferase





Coronaviruses – Replication cycle





Coronaviruses – Replication complex

Model of Putative Coronavirus Replisome




Coronaviruses – Replication cycle







- Spatial compartment for replication and transcription
- Concentration of macromolecules
- “Hiding” of replication intermediates from cytosolic sensors





Coronaviruses – Replication cycle




Coronaviruses - Replication





Coronaviruses - Replication



Coronaviruses – Translation/Assembly



Coronaviruses – Translation/Assembly



**ER and ER-GOLGI Intermediate compartment:
(ERGIC) Assembly and budding site**

Blue arrows: SARS-CoV-2 assembly intermediates


Pink arrows: Transport vesicles

Black arrows: vesicles containing virus particles

DMV: Double membrane vesicles


SMV: Single membrane vesicles

Coronaviruses – Egress




Coronaviruses – Egress

Egress through exocytosis-like mechanism (main) or lysosomal trafficking (alternative)




SARS-CoV
MERS-CoV
SARS-CoV-2



SARS-CoV

Severe acute respiratory Coronavirus




SARS-CoV - Transmission

Friday,
Feb 21 2003

Metropole Hotel
Professor Liu
checks into the
9th floor

- Prof. Liu enters the hotel
- In the elevator he meets
 - Businessmen from the US
 - Lady from Toronto
- In the hallway:
 - Stewardesses from Singapur
- A couple of days later....

.... he dies!




SARS-CoV - Transmission

Friday,
Feb 21 2003

Metropole Hotel
Professor Liu
checks into the
9th floor




Next days ...






Finally ... 8'098 infected, ... 774 (9.6%) died

60




2002/2003 SARS

- Severe atypical pneumonia in Guangdong Province, China → 24 countries affected
- 20-30% of infected: ICU, external Respiration necessary
- 774 Deaths, ca. 8.000 infected → 10 % Mortality
- Droplets/Aerosols, „Superspreader“
- No new natural infections since 2004





MERS-CoV

Middle East Respiratory Syndrome Coronavirus




2012 MERS

- Identified in Saudi Arabia
- So far 2.589 laboratory confirmed cases in 27 countries (940 deaths)
- Acute respiratory syndrome, Pneumonia
 - Ca. 34.3% CFR



MERS-CoV - Transmission

- Zoonotic transmission
 - Close contact to infected animal
 - Camels are zoonotic reservoir
- Human-to-human transmission
(not very efficient)
- Aerosol/Droplet





SARS-CoV-2

Severe Acute Respiratory Syndrome Coronavirus - 2




A novel Disease breaks out




Next Generation Sequencing:


Genom




Fragmentation



Adapter Ligation




Cluster
Amplification




Assembly



Annotation



Identification



The NEW ENGLAND JOURNAL of MEDICINE



BRIEF REPORT

A Novel Coronavirus from Patients with Pneumonia in China, 2019



Na Zhu, Ph.D., Dingyu Zhang, M.D., Wenling Wang, Ph.D., Xingwang Li, M.D., Bo Yang, M.S., Jingdong Song, Ph.D., Xiang Zhao, Ph.D., Baoying Huang, Ph.D., Weifeng Shi, Ph.D., Roujian Lu, M.D., Peihua Niu, Ph.D., Faxian Zhan, Ph.D., Xuejun Ma, Ph.D., Dayan Wang, Ph.D., Wenbo Xu, M.D., Guizhen Wu, M.D., George F. Gao, D.Phil., and Wenjie Tan, M.D., Ph.D., for the China Novel Coronavirus Investigating and Research Team

SUMMARY


In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)



SARS-CoV-2 - Timeline




SARS-CoV-2 - Pandemic





December 2019 (Wuhan)
Caused COVID-19 Pandemic



Johns Hopkins University (10/03/2023)




SARS-CoV-2 – Origin



SARS-CoV-2 - Transmission




SARS-CoV-2 - Transmission




SARS-CoV-2

How is the virus spread?

The virus can spread easily




The virus remains in the airways




Reproduction Number

Average Basic Reproduction Number (R_0) of common viral infections



*Mode of transmission:
air droplets



The **average basic reproduction number (R_0)** is an epidemiologic metric that describes the transmissibility of infectious agents. R_0 measures the expected number of secondary infections produced by a single infectious individual in a susceptible population during the mean infectious period.

Superspreader – SARS-CoV-2

Transmission

- Social
- Family
- Work
- Local travel

Ⓜ Wedding

Ⓣ Temple

Ⓟ Bar

Source



● Imported source

● Local source



Intervention

□ Government quarantine


□ Home quarantine



SARS-CoV-2 – Tropism




- Entry mediated by ACE2 und TMPRSS2 (Lunge)




COVID-19 – Multi Organ Tropism



Heart/Circulation



Pulmonal Disease




Gastrointestinal symptoms





COVID-19

Neurological Symptoms





Dermatological Manifestation





COVID-19 – Multi Organ Tropism


Host Tissues Known to Express ACE2



COVID-19 – Course of disease




COVID 19 – Cytokine Storm




Cytokine Storm

- ① Coronavirus infects lung cells
- ② Immune cells, including macrophages, identify the virus and produce cytokines
- ③ Cytokines attract more immune cells, such as white blood cells, which in turn produce more cytokines, creating a cycle of inflammation that damages the lung cells
- ④ Damage can occur through the formation of fibrin
- ⑤ Weakened blood vessels allow fluid to seep in and fill the lung cavities, leading to respiratory failure




SARS-CoV-2 - Diagnostic

I) Direct (Virus)




- RT-PCR
- Sequencing
- Antigen-ELISA
- Rapid Antigen Test
- Western Blot
- ...


II) Indirect (Immunoreaction)



- Antibody-ELISA
- Neutralization Assay
- T-Cell activity
- ...




SARS-CoV-2 - Antivirals




SARS-CoV-2 - Antivirals

Drug	Class	Target	Application
Remdesivir	Nucleoside-Analog	Replication	I.V
Paxlovid (Nirmatrelvir/ Ritonavir)	Protease inhibitor	M ^{PRO}	Oral
Molnupiravir	Nucleoside derivate	Copying errors	Oral
Bebtelovimab	mAB	Spike	I.V.


Several more.....




SARS-CoV-2 - Vaccines



SARS-CoV-2 Variants




Coronaviruses – Mutations




Virus




Host



Coronaviruses – Replication errors



Coronaviruses – Replication errors




Errors:




DNA polymerase: 1: 10^7 – 10^9 nucleotides

RNA polymerase: 1: 1000 – 10.000 nucleotides


Coronaviruses: Proof-reading function (NSP14)



Coronaviruses – Replication errors




SARS-CoV-2 - Variants




Alpha B.1.1.7	Beta B.1.351	Gamma B.1.1.28.1	Delta B.1.617.2	Omikron B.1.1.529
Entdeckung: Sept. 2020	Entdeckung: Okt. 2020	Entdeckung: Jan. 2021	Entdeckung: Okt. 2020	Entdeckung: Nov. 2021
Spike-Mutationen: 7 Mutationen: N501Y, A570D, D614G, P681H, T716I, S982A, D1118H Zwei Deletionen: H69-V70del Y144del	Spike-Mutationen: 9 Mutationen: L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V Eine Deletion: LAL 242-244 del	Spike-Mutationen: 12 Mutationen: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F	Spike-Mutationen: 7 Mutationen: T19R, del157-158, L452R, T478K, D614G, P681R, D950N Zwei kritische Substitutionen: L452R, E484Q	Spike-Mutationen: 30 Mutationen: A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493RQ, G, G98496, N Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F

**GELBE
LISTE.**
PHARMINDEX




SARS-CoV-2 - Variants



Spike Mutations: Can affect infectivity and antibody recognition

SARS-CoV-2 - Omicron





Thank you for your attention

